A recent study showed that vaccination with BNT162b2 induced highly targeted IgG anti-S Abs whose levels were higher than those in mildly or moderately ill COVID-19 patients but similar to those who were severely ill, at days 28 and 42 (preprint data, not yet peer reviewed) [21]. Here, DDX41 is linked to COVID-19.